Investigator Studies Program (MISP): Pneumococcus
Effective March 2019, the Pneumococcus Investigator Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to May 19, 2019. This is a competitive process that will be conducted by the Pneumococcus MISP in 2019. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below.

The following areas are of interest to Investigator Studies Program Committee:
  • Identifying disease-causing pneumococcal serotypes using the Merck urine assay, with focus on non-bacteremic pneumonia in adults
  • Studies evaluating the epidemiology, burden of illness and health-economic impact of pneumococcal serotypes in regions, countries or populations, including in areas in which these data are limited or outdated
    • Vaccine serotypes in Pneumococcal Conjugate Vaccine (PCV)10, PCV13, PCV15, Pneumococcal Polysaccharide Vaccine (PPV)23, and emerging non-vaccine serotypes
    • Disease manifestations of interest include
      • non-invasive pneumococcal pneumonia in adults
      • acute otitis media in children
    • Antibiotic resistance of vaccine and non-vaccine serotypes causing invasive and non-invasive pneumococcal disease in children and adults
    • Impact of pediatric vaccination programs on the prevalence and serotype distribution of nasopharyngeal carriage in adults, particularly serotypes contained in PPV23.
  • The epidemiology of the pneumococcal serotypes contained in PPV23, in settings or countries in which PCV13 has been introduced, for all age groups, and where data are currently limited or outdated
  • Studies evaluating efficacy/effectiveness, safety, health economic impact and population-level impact of revaccination of PPV23
  • Epidemiological studies of effectiveness and durability of sequential use of PCV and PPV
  • The prevalence and/or serotype distribution of pneumococcal carriage, risk factors for pneumococcal carriage, and the links between pneumococcal carriage and disease.
  • Studies that advance the understanding of immunology and vaccine response with respect to correlates of immune protection against pneumococcal disease in adults and acute otitis media and carriage in infants and children
  • Generation of immunological memory and durability of protective responses for conjugate and non-conjugated polysaccharide vaccines, stratified according to subject populations e.g., elderly and infants.
  • Barriers to, and facilitators of, completion of sequential vaccination with PCV and PPV in adults.

Please complete a full protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US) or your MSD country representative (outside US). The proposals will be collectively reviewed and selected by the Pneumococcus MISP Committee.

Critical Activities and Timelines:
Activity 1st Review Cycle
Full Protocol Submission with Detailed Budget May 19, 2019
Final Comments to Investigator July 19, 2019

MISP Information
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator Studies Program should contact their local MSD office.